RxDoctor Payments Data

James Case, MD

Neurology · Dakota Dunes, SDNPI 1992708853

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 106 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 25.8% of the total. Reporting peaked in 2023 at $959 and has fallen 61.3% since, to $371 in 2025.

$2,510in general payments, 2019–2025

Across 106 payments — averaging $23.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$648
  • AbbVie$545
  • Acadia Pharmaceuticals Inc$211
  • Argenx US, Inc.$181
  • Itamar Medical Inc$135
  • Lilly USA, LLC$118
  • plus $672 from 14 others
$25,000in research payments, 2019–2025

Across 1 payment — averaging $25,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GE HealthCare$25K

What the payments were for

  • Food & beverage$2,510100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,510 in reported general payments places this provider in the 70th percentile of 49 neurology providers in South Dakota.

See all neurology providers in South Dakota

Medicare billing

Part B allowed, 2024
$119,388
Medicare patients
346
Services billed
7,461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Carbamazepine ErCarbamazepine17$2,266
Carbidopa-LevodopaCarbidopa/Levodopa128$2,213
Gabapentin58$1,244
Ramelteon13$1,157
Levetiracetam42$1,096
Baclofen47$682
Lamotrigine51$640
Memantine Hcl48$542
Pramipexole DihydrochloridePramipexole Di-Hcl18$532
Oxcarbazepine14$338
Donepezil Hcl46$274
Duloxetine Hcl15$136
Clonazepam19$119
Primidone12$49

Paid to pharmacies, not to this prescriber.

Other neurology in Dakota Dunes

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →